{
  "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5",
  "docSlug": "225408061c3ed04b028031d27cf2467f",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides",
  "authorId": "immix-biopharma",
  "authorName": "ImmixBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 62,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a comparative layout to position NXC-201 as a superior, one-time monotherapy against current multi-drug, weekly treatment regimens.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/39",
  "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5",
  "deckJsonHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5.json",
  "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.17,
        "y": 0.4
      },
      "kind": "callout",
      "text": "NXC-201 – 100% ORR. One-time treatment | Monotherapy | All Relapsed/Refractory ALA Patients. 32,752 Eligible U.S. AL Amyloidosis Patients",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4cc881e5-955a-49e2-88eb-85cbbdeab2f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Note: Public information development plans as of 2023. Source: Dima D, et al. Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation. JCO Oncol Pract. 2023...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ec808bd-b5e3-4cdc-9dc2-016d596bf21f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "image",
      "text": "Prothena, Johnson & Johnson, Venclexta, Abbvie, Genentech, AstraZeneca, Caelum Biosciences",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fafa4767-6e3f-4e05-89f8-65ccdfe7d986",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Newly diagnosed US incidence ~4,000. Relapsed/Refractory ~3,040. Estimated relapsed/refractory US prevalence ~29,712 in 2023. Eligible R/R ALA Patients ~32,752.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d05e1de-bdbb-4cb9-ba75-4578ead1947e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.68,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96354f4a-4862-447e-ab23-e79fae4f2fde",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "8cd27cac-b1c9-4bcf-bd75-f83893106b2d",
      "evidence": "The slide segments the patient population from incidence to total eligible R/R patients.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 62,
      "from": 35,
      "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}